P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY

• Jonathon Cohen,
• Lindsey Roeker,
• Chan Cheah,
• Toby Eyre,
• Krish Patel,
• Jennifer Woyach,
• John Seymour,
• Michael Wang,
• Yucai Wang,
• Angely Loubert,
• Nalin Payakachat,
• Lisa Hess,
• Paolo Abada,
• Anthony R. Mato,
• Paolo Ghia

Affiliations

Jonathon Cohen

1 Emory Winship Cancer Institute, Atlanta, United States

Lindsey Roeker

2 Memorial Sloan Kettering Cancer Center, New York, United States

Chan Cheah

3 Linear Clinical Research and Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, Australia

Toby Eyre

4 Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Krish Patel

5 Hematology and Cellular Therapy Center, Swedish Cancer Institute, Seattle, United States

Jennifer Woyach

6 The Ohio State University Comprehensive Cancer Center, Columbus, United States

John Seymour

7 Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Parkville, Australia

Michael Wang

8 MD Anderson Cancer Center Mays Clinic, Houston, United States

Yucai Wang

9 Mayo Clinic Rochester MN, Rochester, United States

Angely Loubert

10 Modus Outcomes, a Division of THREAD, Lyon, France

Nalin Payakachat

11 Eli Lilly and Company, Indianapolis, United States

Lisa Hess

11 Eli Lilly and Company, Indianapolis, United States

Paolo Abada

12 Loxo@Lilly, Indianapolis, United States

Anthony R. Mato

2 Memorial Sloan Kettering Cancer Center, New York, United States

Paolo Ghia

13 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy